A Single-Blinded Randomized, Placebo-Controlled, Staggered-Parallel, Escalating-Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral SB756050 Administered for 6 Days to Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2017
At a glance
- Drugs SB 756050 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- 10 Jun 2017 Biomarkers information updated
- 05 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Feb 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.